Lylunn personal page - To The Moon

Lylunn

No personal profile

5Follow

0Followers

0Topic

0Badge

2021-04-14

Nice

Moderna and Novavax added to 'mix and match' COVID-19 vaccine trial

2021-04-14

Okay

Global PC Demand Grew At Fastest Pace Since Dot Com Years

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3580963391553114,"uuid":"3580963391553114","gmtCreate":1617870127322,"gmtModify":1617870127322,"name":"Lylunn","pinyin":"lylunn","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":344837835,"gmtCreate":1618395052327,"gmtModify":1704710136419,"author":{"id":"3580963391553114","authorId":"3580963391553114","authorIdStr":"3580963391553114","name":"Lylunn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580963391553114"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344837835","repostId":"2127765025","repostType":4,"repost":{"id":"2127765025","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1618392900,"share":"https://ttm.financial/m/news/2127765025?lang=&edition=fundamental","pubTime":"2021-04-14 17:35","market":"hk","language":"en","title":"Moderna and Novavax added to 'mix and match' COVID-19 vaccine trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2127765025","media":"Dow Jones","summary":"Results could allow more flexibility in giving second shots.A major U.K. trial looking at whether CO","content":"<blockquote>Results could allow more flexibility in giving second shots.</blockquote><p>A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.</p><p>The Com-Cov , and vice versa.</p><p>The expanded study  will look to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.</p><p>These volunteers, who will have received either drug company AstraZeneca's vaccine, which was developed together with the University of Oxford, or the Pfizer--BioNTech vaccine, will randomly receive either the same shot, or the <a href=\"https://laohu8.com/S/AONE\">one</a> from biotech Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> or the <a href=\"https://laohu8.com/S/AONE.U\">one</a> from pharmaceutical Novavax <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a>, for a second dose.</p><p>The six new \"arms\" of the trial will each involve 175 people, bringing the total number of participants in the trial to 1,050.</p><p>Working across eight sites in the U.K., researchers will monitor the immune system responses, as well as any adverse reactions, such as fever, to these new combinations of vaccines. The trial is designed as a so-called 'non-inferiority' study, which means its intent is to demonstrate that mixing isn't substantially worse than not mixing.</p><p>\"If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their COVID-19 immunization course more rapidly,\" said Matthew Snape, associate professor in pediatrics and vaccinology at the University of Oxford and chief investigator on the trial, in a statement.</p><p>\"This would also create resilience within the system in the event of a shortfall in availability of any of the vaccines,\" Snape added.</p><p>The expanded study comes after the rollout of the Moderna vaccine in England started this week across the U.K.</p><p>The Novavax vaccine was found to be 96% effective.</p><p>Results from the original Com-Cov trial, which only used the AstraZeneca and Pfizer--BioNTech vaccine, are expected in May, while results of the second phase should come out by June or July, although the study will run for a year.</p><p>If it shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation  would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna and Novavax added to 'mix and match' COVID-19 vaccine trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna and Novavax added to 'mix and match' COVID-19 vaccine trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-04-14 17:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>Results could allow more flexibility in giving second shots.</blockquote><p>A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.</p><p>The Com-Cov , and vice versa.</p><p>The expanded study  will look to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.</p><p>These volunteers, who will have received either drug company AstraZeneca's vaccine, which was developed together with the University of Oxford, or the Pfizer--BioNTech vaccine, will randomly receive either the same shot, or the <a href=\"https://laohu8.com/S/AONE\">one</a> from biotech Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> or the <a href=\"https://laohu8.com/S/AONE.U\">one</a> from pharmaceutical Novavax <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a>, for a second dose.</p><p>The six new \"arms\" of the trial will each involve 175 people, bringing the total number of participants in the trial to 1,050.</p><p>Working across eight sites in the U.K., researchers will monitor the immune system responses, as well as any adverse reactions, such as fever, to these new combinations of vaccines. The trial is designed as a so-called 'non-inferiority' study, which means its intent is to demonstrate that mixing isn't substantially worse than not mixing.</p><p>\"If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their COVID-19 immunization course more rapidly,\" said Matthew Snape, associate professor in pediatrics and vaccinology at the University of Oxford and chief investigator on the trial, in a statement.</p><p>\"This would also create resilience within the system in the event of a shortfall in availability of any of the vaccines,\" Snape added.</p><p>The expanded study comes after the rollout of the Moderna vaccine in England started this week across the U.K.</p><p>The Novavax vaccine was found to be 96% effective.</p><p>Results from the original Com-Cov trial, which only used the AstraZeneca and Pfizer--BioNTech vaccine, are expected in May, while results of the second phase should come out by June or July, although the study will run for a year.</p><p>If it shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation  would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127765025","content_text":"Results could allow more flexibility in giving second shots.A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.The Com-Cov , and vice versa.The expanded study  will look to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.These volunteers, who will have received either drug company AstraZeneca's vaccine, which was developed together with the University of Oxford, or the Pfizer--BioNTech vaccine, will randomly receive either the same shot, or the one from biotech Moderna $(MRNA)$ or the one from pharmaceutical Novavax $(NVAX)$, for a second dose.The six new \"arms\" of the trial will each involve 175 people, bringing the total number of participants in the trial to 1,050.Working across eight sites in the U.K., researchers will monitor the immune system responses, as well as any adverse reactions, such as fever, to these new combinations of vaccines. The trial is designed as a so-called 'non-inferiority' study, which means its intent is to demonstrate that mixing isn't substantially worse than not mixing.\"If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their COVID-19 immunization course more rapidly,\" said Matthew Snape, associate professor in pediatrics and vaccinology at the University of Oxford and chief investigator on the trial, in a statement.\"This would also create resilience within the system in the event of a shortfall in availability of any of the vaccines,\" Snape added.The expanded study comes after the rollout of the Moderna vaccine in England started this week across the U.K.The Novavax vaccine was found to be 96% effective.Results from the original Com-Cov trial, which only used the AstraZeneca and Pfizer--BioNTech vaccine, are expected in May, while results of the second phase should come out by June or July, although the study will run for a year.If it shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation  would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344837122,"gmtCreate":1618395016166,"gmtModify":1704710136584,"author":{"id":"3580963391553114","authorId":"3580963391553114","authorIdStr":"3580963391553114","name":"Lylunn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580963391553114"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344837122","repostId":"1165784603","repostType":4,"repost":{"id":"1165784603","pubTimestamp":1618392235,"share":"https://ttm.financial/m/news/1165784603?lang=&edition=fundamental","pubTime":"2021-04-14 17:23","market":"us","language":"en","title":"Global PC Demand Grew At Fastest Pace Since Dot Com Years","url":"https://stock-news.laohu8.com/highlight/detail?id=1165784603","media":"zerohedge","summary":"Demand for computers is still extraordinarily high, continuing a boom that began last year during th","content":"<p>Demand for computers is still extraordinarily high, continuing a boom that began last year during the virus pandemic when tens of millions of people were forced into government lockdowns as they needed new computers to work at home.</p>\n<p>Worldwide PC shipments jumped 32% in 1Q21 over the same period last year, according to research firmGartner. They estimate that 69.9 million laptops and desktops were shipped in the first quarter. In terms of the month's growth rate, PC shipments to retailers and other vendors were at the highest level since 2000.</p>\n<p>According to the report, the top PC makers are Lenovo, HP, Dell, Apple, Acer, and Asus.</p>\n<p><img src=\"https://static.tigerbbs.com/00f19c0c7f7f569e1dc48271985ec9ed\" tg-width=\"500\" tg-height=\"328\" referrerpolicy=\"no-referrer\">In the early days of the virus pandemic, PC shipments plunged before rapidly increasing months after as companies adjusted to remote-work or hybrid work environments for their employees. Total PC shipments worldwide have been siding for years and just registered their highest level since 2015, when they printed at 71.7 million.</p>\n<p><img src=\"https://static.tigerbbs.com/eca377423af6d1e640b451b22fdc3562\" tg-width=\"500\" tg-height=\"272\">Monday's report suggests the abrupt shift to working from home may become normalized in a post-COVID world. The future remains uncertain, but PC shipments globally continue to rise, lending credit that the pandemic will forever change how some people work.</p>\n<p>An increase in PC demand will require exceptional demand for chips and other components during a worldwide semiconductor shortage. This could result in lower PC shipment numbers as semiconductor component markets remain tight.</p>\n<p>Days ago, we&nbsp;told&nbsp;readers how an inexpensive $1 display chip was wreaking havoc across global supply chains. The shortage of driver chips has made it remarkably painful for supply chains of auto and tech industries who have&nbsp;scaled back or suspended production&nbsp;of certain products in recent months due to their inability to source chips.</p>\n<p>To make matters worse, cold weather in Texas in February knocked a decent chunk of US production. A&nbsp;fire at a Japanese chip factory&nbsp;in March forced production to shut down for a month.</p>\n<p>Semiconductor companies like Samsung Electronics and Taiwan Semiconductor Manufacturing warned they're both struggling to keep up with demand despite running factories at over 100% capacity.</p>\n<p><i>\"The supply chain was completely disrupted one year ago, and the supply chain is disrupted right now because of a global semiconductor shortage,\" Gartner researcher Mikako Kitagawa toldCNBC.</i></p>\n<p>One striking feature of the semiconductor shortage is that it could hurt the economic recovery. Goldman Sachs economist Jan Hatzius told clients the&nbsp;chip shortage is not the only shortage&nbsp;and could persist into 2022.</p>\n<p><img src=\"https://static.tigerbbs.com/145dd080dd90adedc44171964717f843\" tg-width=\"500\" tg-height=\"345\">Kitagawa added,<i>\"We believe, at least this year, especially in the first half of this year, PC demand will remain strong. The question is how strong it's going to be in the second half of this year to next year.\"</i></p>\n<p>It's reasonable to conclude that PC demand worldwide will remain elevated even after stay-home restrictions ease because of a permanent shift of people working at home or at least on a hybrid work basis.</p>\n<p>Another analysis via research firm Canalys estimates worldwide PC market increased by a whopping 55% in the quarter, and IDC estimates 55% growth as well.</p>\n<p>Soaring PC demand during one of the worst ever global chip shortages is not an ideal combination as it could damper future PC production.</p>\n<p><i>Readers should ask how long will all of this pull forward in PC&nbsp;demand will last?</i></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global PC Demand Grew At Fastest Pace Since Dot Com Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal PC Demand Grew At Fastest Pace Since Dot Com Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 17:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/technology/global-pc-demand-grew-fastest-pace-dot-com-years?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Demand for computers is still extraordinarily high, continuing a boom that began last year during the virus pandemic when tens of millions of people were forced into government lockdowns as they ...</p>\n\n<a href=\"https://www.zerohedge.com/technology/global-pc-demand-grew-fastest-pace-dot-com-years?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.zerohedge.com/technology/global-pc-demand-grew-fastest-pace-dot-com-years?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165784603","content_text":"Demand for computers is still extraordinarily high, continuing a boom that began last year during the virus pandemic when tens of millions of people were forced into government lockdowns as they needed new computers to work at home.\nWorldwide PC shipments jumped 32% in 1Q21 over the same period last year, according to research firmGartner. They estimate that 69.9 million laptops and desktops were shipped in the first quarter. In terms of the month's growth rate, PC shipments to retailers and other vendors were at the highest level since 2000.\nAccording to the report, the top PC makers are Lenovo, HP, Dell, Apple, Acer, and Asus.\nIn the early days of the virus pandemic, PC shipments plunged before rapidly increasing months after as companies adjusted to remote-work or hybrid work environments for their employees. Total PC shipments worldwide have been siding for years and just registered their highest level since 2015, when they printed at 71.7 million.\nMonday's report suggests the abrupt shift to working from home may become normalized in a post-COVID world. The future remains uncertain, but PC shipments globally continue to rise, lending credit that the pandemic will forever change how some people work.\nAn increase in PC demand will require exceptional demand for chips and other components during a worldwide semiconductor shortage. This could result in lower PC shipment numbers as semiconductor component markets remain tight.\nDays ago, we told readers how an inexpensive $1 display chip was wreaking havoc across global supply chains. The shortage of driver chips has made it remarkably painful for supply chains of auto and tech industries who have scaled back or suspended production of certain products in recent months due to their inability to source chips.\nTo make matters worse, cold weather in Texas in February knocked a decent chunk of US production. A fire at a Japanese chip factory in March forced production to shut down for a month.\nSemiconductor companies like Samsung Electronics and Taiwan Semiconductor Manufacturing warned they're both struggling to keep up with demand despite running factories at over 100% capacity.\n\"The supply chain was completely disrupted one year ago, and the supply chain is disrupted right now because of a global semiconductor shortage,\" Gartner researcher Mikako Kitagawa toldCNBC.\nOne striking feature of the semiconductor shortage is that it could hurt the economic recovery. Goldman Sachs economist Jan Hatzius told clients the chip shortage is not the only shortage and could persist into 2022.\nKitagawa added,\"We believe, at least this year, especially in the first half of this year, PC demand will remain strong. The question is how strong it's going to be in the second half of this year to next year.\"\nIt's reasonable to conclude that PC demand worldwide will remain elevated even after stay-home restrictions ease because of a permanent shift of people working at home or at least on a hybrid work basis.\nAnother analysis via research firm Canalys estimates worldwide PC market increased by a whopping 55% in the quarter, and IDC estimates 55% growth as well.\nSoaring PC demand during one of the worst ever global chip shortages is not an ideal combination as it could damper future PC production.\nReaders should ask how long will all of this pull forward in PC demand will last?","news_type":1},"isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":344837835,"gmtCreate":1618395052327,"gmtModify":1704710136419,"author":{"id":"3580963391553114","authorId":"3580963391553114","authorIdStr":"3580963391553114","name":"Lylunn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580963391553114"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344837835","repostId":"2127765025","repostType":4,"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344837122,"gmtCreate":1618395016166,"gmtModify":1704710136584,"author":{"id":"3580963391553114","authorId":"3580963391553114","authorIdStr":"3580963391553114","name":"Lylunn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580963391553114"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344837122","repostId":"1165784603","repostType":4,"isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}